Avidity Biosciences, Inc., was incorporated under the laws of the State of Delaware on November 13, 2012. The company is a biopharmaceutical company. The Company has pioneered a new class of oligonucleotide-based therapies, called antibody oligonucleotide conjugates (AOCs), designed to overcome the current limitations of oligonucleotide therapies to treat a variety of serious diseases. The company utilizes its proprietary AOC platform to design, plan and develop therapies that combine the precision of monoclonal antibodies (mAbs) with tissue-selective and oligonucleotide therapies to access previously unabsorbable tissue and cell types and more effectively target the underlying genetic drivers of the disease.